Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Cantrixil proves highly effective at killing human ovarian stem cells in pre-clinical study

US-Australian drug discovery company, Novogen Ltd, and its subsidiary, CanTx, Inc., and Yale University, on March 27 released pre-clinical data on experimental anti-cancer drug, Cantrixil. The data was presented as an oral presentation by Professor Gil Mor MD PhD of Yale Medical School to the 62nd Annual Scientific Meeting of the Society of Reproductive Investigation in San Francisco, CA.

30 Mar 2015

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that the China Food and Drug Administration (CFDA) has approved the Company's application to conduct a Phase 2 global clinical trial in ovarian clear cell carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076.

30 Mar 2015

Combination treatment improves outcomes in women with ovarian cancer

Medical researchers are always looking for ways to prevent or cure cancer. Given the complexity of this disease, reaching these milestones has been difficult.

30 Mar 2015

Experimental immunotherapy shows promise in women with stage III or IV ovarian cancer

Personalized medicine is getting closer to reality for women with late-stage ovarian cancer. An experimental immunotherapy is in the works that can target an individual woman's tumor and extend the time period between initial treatment and the cancer's return.

29 Mar 2015

Philip Low to be recognized with AACR Award for Outstanding Achievement in Chemistry in Cancer Research

The American Association for Cancer Research will recognize Philip S. Low, PhD, with the ninth annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.

26 Mar 2015

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that it has initiated a Phase 2 trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer (TNBC) at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing, China.

25 Mar 2015

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for treatment of gynecological cancers

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian, fallopian tube and primary peritoneal cancers.

25 Mar 2015

DNA samples collected from tampons may help detect endometrial cancer

Researchers at Mayo Clinic have shown that it is possible to detect endometrial cancer using tumor DNA picked up by ordinary tampons. The new approach specifically examines DNA samples from vaginal secretions for the presence of chemical "off" switches — known as methylation — that can disable genes that normally keep cancer in check.

25 Mar 2015

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, today announced top-line data from a randomized Phase II clinical study of its investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS).

23 Mar 2015

Promising new treatment for hereditary breast/ovarian cancer

European scientists recently discovered a novel therapy to treat a subgroup of patients with hereditary breast/ovarian cancer. Both the EU and the US have approved an accelerated procedure to market this promising new treatment with few side effects.

20 Mar 2015

Chemical found in stinging nettles and ants could improve cancer drug

A cancer drug could be made 50 times more effective by a chemical found in stinging nettles and ants, new research finds.

20 Mar 2015

PARP inhibitors can be effective in broader group of patients

A pioneering class of drugs that target cancers with mutations in the BRCA breast cancer genes could also work against tumours with another type of genetic fault, a new study suggests.

20 Mar 2015

ImmunoCellular, PharmaCell sign manufacturing agreement for European production of ICT-107

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma (GBM).

19 Mar 2015

Hormone therapy does not safeguard post-menopausal women against cardiovascular disease

New evidence published today in the Cochrane Library shows that hormone replacement therapy does not protect post-menopausal women against cardiovascular disease, and may even cause an increased risk of stroke.

10 Mar 2015

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Novogen today announces that Professor Gil Mor MD PhD from Yale Medical School will be presenting pre-clinical data on the lead candidate product, Cantrixil, at two upcoming conferences.

6 Mar 2015

VolitionRx begins pilot study to assess feasibility of NuQ assays in detecting prostate cancer

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has initiated a pilot study to assess the feasibility of VolitionRx's proprietary NuQ assays in detecting prostate cancer.

5 Mar 2015

FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of primary peritoneal cancers.

3 Mar 2015

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

2 Mar 2015

Researchers outline personalized surgical approach to ovarian cancer

A surgical algorithm developed and implemented by ovarian cancer specialists at The University of Texas MD Anderson Cancer Center dramatically increases the frequency of complete removal of all visible tumor - a milestone strongly tied to improved survival.

28 Feb 2015

Study finds racial disparities among children with Crohn's disease

A study published recently in the IBD Journal found significant differences in hospital readmissions, medication usage, and both medical and surgical complications of children with Crohn's disease related to race. In the study, black children had a 1.5 times higher frequency of hospital readmissions because of Crohn's disease compared to white children.

28 Feb 2015

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Cantrixil proves highly effective at killing human ovarian stem cells in pre-clinical study

CASI receives CFDA approval for ENMD-2076 Phase 2 clinical trial in ovarian clear cell carcinoma

Combination treatment improves outcomes in women with ovarian cancer

Experimental immunotherapy shows promise in women with stage III or IV ovarian cancer

Philip Low to be recognized with AACR Award for Outstanding Achievement in Chemistry in Cancer Research

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for treatment of gynecological cancers

DNA samples collected from tampons may help detect endometrial cancer

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

Promising new treatment for hereditary breast/ovarian cancer

Chemical found in stinging nettles and ants could improve cancer drug

PARP inhibitors can be effective in broader group of patients

ImmunoCellular, PharmaCell sign manufacturing agreement for European production of ICT-107

Hormone therapy does not safeguard post-menopausal women against cardiovascular disease

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

VolitionRx begins pilot study to assess feasibility of NuQ assays in detecting prostate cancer

FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

Researchers outline personalized surgical approach to ovarian cancer

Study finds racial disparities among children with Crohn's disease

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in